McClarren Financial Advisors’s GSK GSK Stock Holding History

McClarren Financial Advisors’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-101	Closed	-$4K	–	377
2023 Q4	$4K	Buy	+101	New	+$3.63K	﹤0.01%	302

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Holocene Advisors New York $41.5B AUM 42.97% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

McClarren Financial Advisors's GSK Position: Q1 2024 in Review

McClarren Financial Advisors sold out of GSK (GSK) in Q1 2024, closing a stake of 101 shares — an estimated $4K sold.

McClarren Financial Advisors first reported a position in GSK in Q4 2023 and held it in 1 quarter. The position peaked at $4K in Q4 2023. 910 funds tracked by Wall St. Rank hold GSK as of Q1 2024.

McClarren Financial Advisors reported no remaining GSK position as of Q1 2024 after selling out during the quarter.
McClarren Financial Advisors sold 101 GSK shares in Q1 2024, an estimated $4K.
McClarren Financial Advisors first reported a position in GSK in Q4 2023 and held it in 1 quarter.
McClarren Financial Advisors's GSK position peaked at $4K in Q4 2023.
910 funds tracked by Wall St. Rank held GSK as of Q1 2024.

Based on McClarren Financial Advisors's 13F filing for Q1 2024, filed 3 May 2024.